Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer

British Journal of Cancer

Volumn 102, Issue 9, 2010, Pages 1341-1347

  Lee, C K ^a   Stockler, M R ^a,b   Coates, A S ^a,c   Gebski, V ^a   Lord, S J ^a   Simes, R J ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c International Breast Cancer Study Group   (Switzerland)

Author keywords

Advanced breast cancer; Quality of life; Treatment benefits; Treatment toxicity

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PREDNISONE; PROGESTERONE RECEPTOR;

ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; APPETITE; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE FREE INTERVAL; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MOOD; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SELF REPORT; STATISTICAL ANALYSIS; STOMATITIS; THROMBOCYTOPENIA; WEIGHT REDUCTION; WELLBEING;

AFFECT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APPETITE; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HEALTH STATUS; HUMANS; MIDDLE AGED; NAUSEA; NEOPLASM METASTASIS; POSTMENOPAUSE; QUALITY OF LIFE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGRESSION ANALYSIS; SELF CONCEPT; SURVIVAL ANALYSIS; SURVIVORS; VOMITING; WEIGHT LOSS;

EID: 77951666082     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605649     Document Type: Article

References (24)

1. Arbuck S, Ivy S, Setser A (1998) The Revised Common Toxicity Criteria: Version 2.0: CTEP Website. http://ctep.info.nih.gov
2. Coates A, Gebski V, Bishop J, Jeal P, Woods R, Snyder R, Tattersall M, Byrne M, Harvey V, Gill G (1987) Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 317: 1490-1495
3. Coates A, Gebski V, Signorini D, Murray P, McNeil D, Bryne M, Forbes J (1992) Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. J Clin Oncol 10: 1833-1838
4. Coates A, Thomson D, McLeod G, Hersey P, Gill PG, Olver IN, Kefford R, Lowenthal RM, Beadle G, Walpole E (1993) Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer 29A: 1731-1734
5. Coates AS, Hurny C, Peterson HF, Bernhard J, Castiglione-Gertsch M, Gelber RD, Goldhirsch A (2000) Quality-of-life scores predict outcome in metastatic but not early breast cancer. J Clin Oncol 18: 3768-3774
6. Cox DR (1972) Regression models and life-tables. J Royal Stat Soc 34: 187-220
7. Efficace F, Biganzoli L, Piccart M, Coens C, Van Steen K, Cufer T, Coleman RE, Calvert HA, Gamucci T, Twelves C, Fargeot P, Bottomley A (2004) Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer 40: 1021-1030
8. Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P (2005) Survival of metastatic breast carcinoma patients over a 20-year period. Cancer 104: 1742-1750
9. Goodwin PJ, Ennis M, Bordeleau LJ, Pritchard KI, Trudeau ME, Koo J, Hood N (2004) Health-related quality of life and psychosocial status in breast cancer prognosis: analysis of multiple variables. J Clin Oncol 22: 4184-4192
10. Gotay CC, Kawamoto CT, Bottomley A, Efficace F (2008) The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 26: 1355-1363
11. Hortobagyi G, Smith T, Legha S, Swenerton K, Gehan E, Yap H, Buzdar A, Blumenschein G (1983) Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1: 776-786
12. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
13. Kramer JA, Curran D, Piccart M, de Haes JCJM, Bruning P, Klijn J, Van Hoorebeeck I, Paridaens R (2000) Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer 36: 1498-1506
14. Largillier R, Ferrero J-M, Doyen J, Barriere J, Namer M, Mari V, Courdi A, Hannoun-Levi JM, Ettore F, Birtwisle-Peyrottes I, Balu-Maestro C, Marcy PY, Raoust I, Lallement M, Chamorey E (2008) Prognostic factors in 1038 women with metastatic breast cancer. Ann Oncol 19: 2012-2019
15. Lee CK, Lord SJ, Stockler MR, Coates AS, Gebski V, Simes RJ (2010) Historical cross-trial comparisons for competing treatments in advanced breast cancer-an empirical analysis of bias. Eur J Cancer 46: 541-548
16. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
17. Priestman T, Baum M, Jones V, Forbes J (1977) Comparative trial of endocrine versus cytotoxic treatment in advanced breast cancer. Br Med J 1: 1248-1250
18. Quinten C, Coens C, Mauer M, Comte S, Sprangers MAG, Cleeland C, Osoba D, Bjordal K, Bottomley A (2009) Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 10: 865-871
19. Seidman AD, Portenoy R, Yao T-J, Lepore J, Mont EK, Kortmansky J, Onetto N, Ren L, Grechko J, Beltangady M, Usakewicz J, Southrada M, Houston C, McCabe M, Salvaggio R, Thaler H, Norton L (1995) Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. J Natl Cancer Inst 87: 1316-1322
20. Simes R, Gebski V, Coates A, Forbes J, Harvey V, Van Hazel G, Tattersall M, Abdi E, Brigham B (1994) Quality of life with single agent mitozantrone or combination chemotherapy for advanced breast cancer, a randomised trial. Proc Am Soc Clin Oncol 13: 73
21. Spitzer W, Dobson A, Hall J, Chesterman E, Levi J, Shepherd R, Battista RN, Catchlove BR (1981) Measuring the quality of life of cancer patients: a concise QL index for use by physicians. J Chronic Dis 34: 585-597
22. Stockler M, Sourjina T, Harvey V, Frances P, Byrne M, van Hazel G, Fitzharris B, Ackland S, Finch K, Lindsay D, Kato-Fong A, Paksec L, Gebski V, Simes R, Coates A, Forbes J (2007) A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment. Breast Cancer Res Treat 100: S278
23. Weissfeld LA (1989) A multicollinearity diagnostic for models fit to censored data. Commun Stat Theory Methods 18: 2073-2085
24. Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson IC, Hudis C, Muss H, Norton L (2004) Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 22: 2061-2068